Enochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"
![René Sindlev turned troubled biotech Dandrit into a new company by the name of Enochian Biosiences and acquired the rights to a potential cure for HIV. Scientists now question what the company really has in its pipeline. | Photo: David Leth Williams / STF / Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11889127.ece/ALTERNATES/schema-16_9/sindlev3.jpg)
In 2017, Pandora billionaire René Sindlev took matters into his own hands. He had been a key shareholder of the cancer biotech Dandrit for years, but apparently he had had enough: He took the reins and put Dandrit to rest. The company had been working on a failed cancer vaccine, MCV, which according to Sindlev "couldn't even be given away".
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.